A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01056315 |
|
Recruitment Status :
Terminated
(Trial was stopped due to difficult enrolment)
First Posted : January 26, 2010
Results First Posted : May 3, 2012
Last Update Posted : October 28, 2019
|
Sponsor:
Grünenthal GmbH
Information provided by (Responsible Party):
Grünenthal GmbH
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This trial is assessing the analgesic efficacy and safety of a new central analgesic in subjects with pain due to diabetic peripheral neuropathy (DPN).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Painful Diabetic Neuropathy | Drug: GRT3938Y Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 553 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Analgesic Efficacy and Safety of a New Analgesic Compared to Placebo in Subjects With Painful Diabetic Peripheral Neuropathy |
| Study Start Date : | November 2009 |
| Actual Primary Completion Date : | January 2011 |
| Actual Study Completion Date : | January 2011 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: A GRT3983Y
Participants randomly assigned to receive GRT3983Y.
|
Drug: GRT3938Y
Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment. |
|
Placebo Comparator: B Placebo
Participants randomly assigned to placebo.
|
Drug: Placebo
Overencapsulated tablets of placebo, 16 weeks treatment. |
Primary Outcome Measures :
- Average Pain Intensity [ Time Frame: Baseline; last 7 days of 12-week maintenance ]The primary efficacy endpoint is the change from baseline in the mean of the daily average pain intensity scores (on an 11-point NRS) over the last 7 days of the 12-week maintenance (Week 16).
Secondary Outcome Measures :
- Change From Baseline in the Mean of the Daily Average Pain Intensity Scores (on an 11-point NRS) Over the Entire 12-week Maintenance [ Time Frame: Baseline, Daily scores over entire 12 week maintenance ]
- Proportion of Subjects Achieving Various Levels of Pain Improvement (Including 30% and 50%) Based on the Percent Change From Baseline to the Last 7 Days of the 12-week Maintenance on an 11-point NRS (Responder Analysis). [ Time Frame: Baseline, Last 7 days of 12-week maintenance ]
- Change From Baseline in the Mean of the Daily Average Pain Intensity Scores (on an 11-point NRS) Over Each Week of Maintenance. [ Time Frame: Baseline; daily scores over each week of maintenance ]
- Change From Baseline of the Weekly Mean of Night Pain Intensity (on an 11-point NRS). [ Time Frame: Baseline; weekly mean ]
- Change From Baseline of the Weekly Mean of Current Pain Intensity (on an 11-point NRS) in the Evening and in the Morning, Respectively. [ Time Frame: Baseline, weekly mean ]
- Brief Pain Inventory Scores: Changes From Baseline to Day 8, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, and Day 113 (Final Visit). [ Time Frame: Baseline, weekly mean ]
- Neuropathic Pain Symptoms Inventory: Changes From Baseline to Day 8, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99 and Day 113 (Final Visit) [ Time Frame: Baseline, weekly mean ]
- Patient Global Impression of Change Using a 7-point Verbal Rating Scale, on Day 29, Day 71 and Day 113 (Final Visit). [ Time Frame: Day 29, Day 71 and Day 113. ]
- Short Form 36 Health Survey (SF-36®): Changes From Baseline to Day 29, Day 71 and Day 113 (Final Visit). [ Time Frame: Baseline, Day 29, Day 71 and Day 113. ]
- EuroQol-5 Dimension Health Questionnaire: Changes From Baseline to Day 29, Day 71 and Day 113 (Final Visit). [ Time Frame: Baseline, Day 29, Day 71 and Day 113. ]
- Assessment of Each Item of the Leeds Sleep Evaluation Questionnaire: Changes From Baseline to Day 29, Day 71 and Day 113 (Final Visit). [ Time Frame: Baseline, Day 29, Day 71 and Day 113. ]
- Hospital Anxiety and Depression Scale: Changes From Baseline to Day 29, Day 71 and Day 113 (Final Visit). [ Time Frame: Baseline, Day 29, Day 71 and Day 113. ]
- Time to Treatment Discontinuation Due to Lack of Efficacy. [ Time Frame: Baseline to time to treatment discontinuation ]
- Assessment of Rescue Medication Usage During the 4-week Titration. [ Time Frame: 4-week titration phase ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Symmetrical painful diabetic peripheral neuropathy
Exclusion Criteria:
- History of hypersensitivity, allergy or contraindication to opioids and acetaminophen
- Confounding painful conditions
- Significant vascular disease
- History or risk of seizure
- Chronic disease that might effect drug absorption, distribution, metabolism, or excretion
- Female subjects who are being pregnant or breastfeeding
- Evidence or history of alcohol, medication, or drug abuse
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01056315
Locations
Show 61 study locations
Sponsors and Collaborators
Grünenthal GmbH
Investigators
| Study Director: | Study Director | Grünenthal GmbH |
| Responsible Party: | Grünenthal GmbH |
| ClinicalTrials.gov Identifier: | NCT01056315 |
| Other Study ID Numbers: |
131885 |
| First Posted: | January 26, 2010 Key Record Dates |
| Results First Posted: | May 3, 2012 |
| Last Update Posted: | October 28, 2019 |
| Last Verified: | October 2019 |
Keywords provided by Grünenthal GmbH:
|
Analgesia Diabetic Neuropathy Neuropathic pain Painful Chronic pain |
Additional relevant MeSH terms:
|
Peripheral Nervous System Diseases Diabetic Neuropathies Pain Neuromuscular Diseases Nervous System Diseases |
Neurologic Manifestations Diabetes Complications Diabetes Mellitus Endocrine System Diseases |